AtriCure (ATRC) Q3 2024 earnings summary

Executive summary

• Achieved Q3 2024 revenue of $115.9–$116.3 million, up 17.9% year-over-year, with strong growth in both U.S. and international markets and broad-based demand across product lines.

• Adjusted EBITDA reached $7.9 million, a 68% increase from Q3 2023, with positive cash flow of $16.3 million for the quarter.

• Continued investment in innovation, clinical science, and education, with new product launches and expanded indications in the U.S., Europe, and China.

• Focused on treating atrial fibrillation and post-surgical pain, targeting large, underserved patient populations with innovative therapies.

• Leveraging clinical evidence and continuous innovation to expand market presence and improve patient outcomes.

Financial highlights

• U.S. revenue grew 16.8% year-over-year to $95.5 million; international revenue rose 23.3% to $20.5 million.

• Gross margin was 74.9%, down 27 basis points from Q3 2023 due to less favorable geographic and product mix.

• Adjusted EBITDA was $7.9 million, up from $4.7 million in Q3 2023; adjusted loss per share improved to $0.17 from $0.20.

• Cash and investments at quarter-end totaled $130.3 million.

• Operating expenses increased year-over-year, driven by R&D and SG&A expansion.

Outlook and guidance

• Full-year 2024 revenue expected at $459–$462 million, up 15–16% year-over-year.

• Reaffirmed full-year adjusted EBITDA guidance of $26–$29 million and adjusted loss per share of $0.74–$0.80.

• Gross margin for 2024 expected to be consistent with 2023, with some variability from mix.

• Continued investment in growth catalysts and operating leverage expansion.

• Anticipates positive cash generation in Q4, excluding a $12 million IP R&D charge for PFA partnership.